Success Stories: EB-1A Approved for Research Associate in New Jersey in the Field of Cancer Therapeutics
Client’s Testimonial:
Thank you very much for all your help and timely guidance. I greatly appreciate your quick and clear responses throughout the process. I have already referred your group to my friends and will also do so in future.
On May 21st, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a Research Associate in the Field of Cancer Therapeutics (Approval Notice)
Position at the Time of Case Filing: Research Associate
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: May 21st, 2015
Processing Time: 24 days (10 days after premium processing was requested)
In this case, the client that we had the opportunity to work with was a Research Associate from India in the field of Cancer Therapeutics. She had conducted her research in the highly specialized area of on the development of novel anticancer strategies using dietary agents. Her work had resulted in 16 peer-reviewed scientific articles and numerous presentations at national and international conferences; at the time that her case was filed, her publications had been cited at least 145 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of her work. She had also reviewed 31 manuscripts for distinctive, internationally-circulated journals. Her superior level of expertise was confirmed in the following quote from an independent recommender, “Based on her specific contributions and the level of skill and expertise that she has routinely displayed, I think it is in the best interest of the United States to ensure that [Client] continues in her research efforts within the country.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that she sought to remain in the United States to continue work in the area of Cancer Therapeutics, and that her continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, her case was approved in 24 days.